Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT02013167 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

405

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab
DRUG: Standard of Care Chemotherapy

Sponsor

Amgen